Effect of dipyridamole and aspirin on the platelet–neutrophil interaction via the nitric oxide pathway
- 1 May 2000
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 397 (1), 35-41
- https://doi.org/10.1016/s0014-2999(00)00245-4
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Dipyridamole enhances interleukin-1β-stimulated nitric oxide production by cultured rat vascular smooth muscle cellsEuropean Journal of Pharmacology, 1996
- Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytesEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicalsThrombosis Research, 1992
- Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxideEuropean Journal of Pharmacology, 1991
- Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factorThrombosis Research, 1990
- Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study GroupDiabetes, 1989
- Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: an in vitro studyScandinavian Journal of Haematology, 1986
- Clinical pharmacokinetics of dipyridamoleThrombosis Research, 1983
- Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: Possible explanation of mechanism of inhibition of platelet functionLife Sciences, 1975
- The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.Journal of Clinical Investigation, 1975